Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Recursion describes itself as a clinical stage TechBio company that uses its proprietary Recursion OS platform to analyze biological and chemical datasets. The company operates laboratories capable of ...

Republican lawmakers decry Intel's testing of Chinese-linked tools after Reuters report Republican lawmakers accused Intel this week of threatening U.S. national security after Reuters revealed the ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Morningstar Data+Analytics combines our renowned independent research and ratings with coverage and analysis of the expanding universe of investment opportunities. Reveal actionable insights about a ...

Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...